Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Approves HPV Vaccine for Adults up to 45

By Seth Augenstein | October 9, 2018

The vaccine for human papillomavirus (HPV), a sexually-transmitted virus spread to 14 million new Americans each year and causing more than 30,000 cancers every year, has successfully slowed the spread of the STD among the youngest segments of the population over the last decade-plus.

Now the vaccine has been approved for an older segment of the population—ages 27 through 45, according to a U.S. Food and Drug Administration announcement Friday.

The population-level effort is an attempt to reduce the number of infections, and boost immunity among the “herd,” according to health officials.

“Today’s approval represents an important opportunity to help prevent HPV-related disease and cancers in a broader age range,” said Peter Marks, the director of the Centers for Biologics Evaluation and Research at the FDA.

The first Gardasil vaccine was approved by the FDA in 2006. Its first version covered four HPV types that were the most-common cancer causers among the 100 strains known circulating in the population. The updated Gardasil 9, covering nine strains, was approved by the FDA in 2015, and was approved for both sexes between the ages of nine and 26.

Statistics show that the nine strains of the virus covered by the Gardasil 9 vaccine can prevent more than 90 percent of the cancers of the cervix, anus, penis and throat.

Prior to this FDA approval, a Gardasil study undertaken among 3,200 women who were between 27 and 45 were monitored for an average of more than three years. The conclusion: the shots were 88 percent effective in preventing viral symptoms of persistent infection, including genital warts, precancerous lesions of the vulva and vagina and cervix, and cervical cancer. 

Australia is in many ways leading the world in HPV vaccination rates. The country has a fully-funded national program that began in 2007. In 2016, the full-course, triple-dose coverage rates for children turning 15 was 78.6 percent for girls and 72.9 percent for boys.

A study last week in The Lancet projects “cervical cancer elimination” in the country by the mid-21stcentury. (The current rate of the disease is seven in 100,000 women, and by 2066 they project it to fall to one in 100,000, due to the national vaccine and screening programs.)

The U.S. vaccination rate is far lower. According to CDC data, just half of all adolescents were completely inoculated with all the doses of Gardasil as of last year—although about 66 percent of those aged 13 to 17 had received the first dose. That first-dose rate has increased by 5 percentage points each year, from 2013 to 2017, according to the federal health agency. Some of the morbidity statistics show that vaccine rates in American rural areas is significantly lower than urban areas.

The FDA approval of the Gardasil vaccine for adults does not change epidemiological guidance for population-level inoculations. In fact, the CDC has not yet changed its recommendation to include adults up to 45.


Filed Under: Drug Discovery and Development

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE